» Articles » PMID: 7583589

Thrombin Induces the Redistribution and Acute Release of Tissue Factor Pathway Inhibitor from Specific Granules Within Human Endothelial Cells in Culture

Overview
Date 1995 Nov 1
PMID 7583589
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Tissue factor pathway inhibitor (TFPI) is a vascular anticoagulant that regulates the tissue (TF)-dependent pathway of coagulation. The majority of intravascular TFPI is thought to be noncovalently bound to the vessel wall. Our immunolocalization studies in cultures of human umbilical vein endothelial cells (HUVEC) and immortalized EA.hy926 cells that TFPI is located in well-defined granules evenly spread over the cell surface and with apical polarization within the cytoplasm. These granules are smaller than and distinct from Weibel-Palade bodies. Upon treatment of cultured cells with low concentrations of thrombin (0.01 to 1 NIH U/mL), a marked redistribution of TFPI, occurred with patching in focal points and increased exposure of both TFPI antigen and anticoagulant activity on the surface of the stimulated endothelial cells. This redistribution was paralleled by an acute release of TFPI in the cell medium. EA.hy926 cells responded more readily to thrombin stimulation than HUVECs. The process was inhibited by both hirudin and anti-thrombin receptor antibody. Our findings demonstrate a novel mechanism by which thrombin may exert a negative feedback control on blood coagulation. Therefore, this pathway can be physiological importance in controlling TF-mediated thrombin generation.

Citing Articles

G-Banding and Molecular Cytogenetics Detect Novel Translocations and Cryptic Aberrations in Human Immortal Endothelial Cells.

Binz R, Pathak R Int J Mol Sci. 2024; 25(14).

PMID: 39063182 PMC: 11276908. DOI: 10.3390/ijms25147941.


Associations of tissue factor and tissue factor pathway inhibitor with organ dysfunctions in septic shock.

Lehner G, Tobiasch A, Perschinka F, Mayerhofer T, Waditzer M, Haller V Sci Rep. 2024; 14(1):14468.

PMID: 38914630 PMC: 11196691. DOI: 10.1038/s41598-024-65262-3.


Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy.

Mast A, Ruf W J Thromb Haemost. 2022; 20(6):1290-1300.

PMID: 35279938 PMC: 9314982. DOI: 10.1111/jth.15697.


Thrombin in complex with dabigatran can still interact with PAR-1 via exosite-I and instigate loss of vascular integrity.

Dolleman S, Agten S, Spronk H, Hackeng T, Bos M, Versteeg H J Thromb Haemost. 2022; 20(4):996-1007.

PMID: 35037739 PMC: 9306515. DOI: 10.1111/jth.15642.


Cellular and molecular mechanisms in COVID-19 coagulopathy: role of inflammation and endotheliopathy.

Cacciola R, Gentilini Cacciola E, Vecchio V, Cacciola E J Thromb Thrombolysis. 2021; 53(2):282-290.

PMID: 34687400 PMC: 8536904. DOI: 10.1007/s11239-021-02583-4.